Oppenheimer 33rd Annual Healthcare Conference

March 13, 2023



Forward-Looking Statements Disclosure

This presentation includes statements relating to the LUNA™ Surgical System next-generation program under development and an update on Asensus' strategic plan. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether we can successfully advance our Performance-Guided Surgery[™] initiative, the risks and uncertainties related to our ability to successfully advance our LUNA System program through development, testing and regulatory approval on the timeline provided, or at all, the

risk that we will not be able to successfully enter into definitive agreements with our collaborators, that the pace of adoption of our products by surgeons will increase, the success and market opportunity of our products, including the ISU and LUNA System, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the risks and uncertainties associated with the Company's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.





We believe in digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery.

The Reality of Surgery

1 in 5 patients undergoing surgery has 1 or more complications¹





Overall profit margin decreased from 5.8% for patients without complications to 0.1% for patients with complications²

Essentially, hospitals make no money if there is a complication.



^{2.} Barry Rosenberg, MD, MBA1; Bennett Lane, MS2; Atul Gawande, MD, MPH3. Economic Impact of Surgical Complications on Hospitals. JAMA Surg. 2016;151(11):1090-1091. doi:10.1001/jamasurg.2016.2308



We Expect More From Surgery

The Future Requires
Different Capabilities and a
Holistic Approach.

Asensus is Uniquely Positioned to Deliver This.

- Increase safety for better outcomes which lead to better patient and provider satisfaction
- Reduce surgical variability and factors that contribute to poor outcomes
- Guide surgeons to successfully navigate when unexpected events occur to effectively reduce surgical errors and complications
- Provide real-time clinical intelligence and capabilities to create more predictable outcomes to meet value-based care constraints



Performance-Guided Surgery

Clinical Intelligence and Real-Time Decision Support Tools That Drive Consistently Superior Outcomes



01 Robotic Manipulation

02 Intra-operative Clinical Guidance

03 Cloud Integration



Senhance Surgical System: Surgery Reimagined

Building the Bridge from Laparoscopy to Performance-Guided Surgery





Digitizing the Interface Between Surgeon and Patient

Delivering Digital Laparoscopy by Maintaining Familiar Motion, Tools, and Techniques



3DHD Visualization

Provides surgeon with additional perception regarding depth and spatial recognition

Eye-Tracking Camera Control

- Camera movement controlled by surgeon's eye gaze
- Eliminates the need to manually adjust camera during procedure

Haptic Feedback

- Only available on Senhance
- Natural sensation of pressure and tension
- Real-time sensory feedback
- Unparalleled level of safety



Robust Global Applicability

> 16 Million Global Annual Addressable Procedure Market

	United States FDA Approved	European Union CE Marked	Japan PMDA Approved	Rest of World Russia, Taiwan, Others
Senhance System	\bigcirc	\bigotimes	\bigcirc	\bigotimes
Intelligent Surgical Unit	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Procedural Indications for Use General		\bigcirc	\bigcirc	\bigcirc
GYN	\bigcirc	\bigcirc	\bigcirc	\bigcirc
Thoracic*		\bigcirc	\bigcirc	\bigcirc
Pediatric		\bigcirc	\bigcirc	
Urology		\otimes	\bigotimes	\bigotimes



LUNA System Overview

Instinctive

Surgeon Console

Collaborative

Robotic Manipulator Arms

Enabling

Instruments





Performance-Guided Surgery

Clinical Intelligence and Real-Time Decision Support Tools That Drive Consistently Superior Outcomes **01** Robotic Manipulation



02 Intra-operative Clinical Guidance

03 Cloud Integration




The Asensus Intelligent Surgical Unit™ (ISU™)





Camera Control and Manipulation





Digital Tags






3D Digital Measurement









Evolution of the ISU





Analytical Tools



Safety Tools





Training Tools



Analytical Tools Example

3D Measurement





Gastric Sleeve Procedure




Measurement with Reference Plane





Safety Tool Example


Establish 'No-Fly' Zones





Training Tool Example

Real-Time Telestration






Performance-Guided Surgery

Clinical Intelligence and Real-Time Decision Support Tools That Drive Consistently Superior Outcomes **01** Robotic Manipulation

02 Intra-operative Clinical Guidance

03 Cloud Integration







Asensus Cloud

Intra-operative

Augmented Intelligence

Pre & Post Op

- Evaluating performance
- Comparative planning
- Workflow optimization
- Training, research, etc.








Performance-Guided Surgery

Clinical Intelligence and Real-Time Decision Support Tools That Drive Consistently Superior Outcomes





Our Path To Market Leadership

Delivering A New Era In Digital Surgery

- 1 Educate surgeons on the benefits of Senhance
- 2 Increase global procedure volumes
- 3 Advance digital capabilities through data collection & analysis
- Develop next generation technology





Educating Surgeons On The Benefits of Senhance

Grow Compelling Set of Data to Demonstrate Clinical and Economic Value

90+

peer review articles to date

- Health economics
 - Cost per procedure
 - Procedure times/workflow
- Usability across specialties
- Clinical outcomes

The TransEnterix European Patient Registry for Robotic-Assisted Laparoscopic Procedures in Urology, Abdominal, Thoracic, and Gynecologic Surgery ("TRUST")

Dietmar Stephan (1.8, Ip Short-term results of robot-assisted colorectal Affiliations + expand cancer surgery using Senhance Digital Laparoscopy PMID: 33513657 DOI: 1 System

Abstract da Vinci & System (Intuit Affiliations + expand monopoly for years after PMID: 35484860 PMCID: PMCS Morrisville, North Carolin Free PMC article movements and is desig

patients after different vi with the Senhance™ digi Abstract

Materials and methods Background: The Senhance Dig PMID: 34591213 DOI: 10.1007/s10029-021-02510-9 surgery with the Senhan States), which was introduced for and bilateral), cholecyste robot following the da Vinci Sur in Europe between Febr, colorectal cancer surgery cases | Abstract

Megumi Sasaki ¹, Yasumitsu Hii Takatsugu Fujii ¹, Naoto Okazai **Inguinal hernia TAPP repair using Senhance** ® **robotic** Introduction: Robotic si Miroshi Sato 1, Shinichi Sakuran platform: first multicenter report from the TRUST

> N E Samalavicius 1 2 3, A Dulskas 4 5, A Sirvys 5, V Klimasauskiene 7, V Janusonis 1 3, T Janusonis 8 9, V Eismontas 1, O Deduchovas 1, D Stephan 10, I Darwich 10, C Poth 11 F Schilcher 31, Y Slabadzin 32, M Kukharchuk 32, F Willeke 30, L Staib 31


Purpose: The purpose of this article was to provide feasibility and safety results of robotic Materials and methods: We rel transabdominal preperitoneal inquinal hernia repair (Robotic TAPP).

outcomes of 55 patients who un Methods: We included 271 cases of robotic inguinal hernia TAPP repair using the Senhance® robotic Results: The median age was 71 platform from four different centers between March 2017 and March 2020. Key data points were mass index was 23.1 kg/m2, Fift intraoperative and postoperative complication rate, operating time, length of hospital stay, surgical technique was ileocecal postoperative pain score and time required to get back to a daily routine that were inserted in the Abdominal Surgery, Thoracic and Gynecologic Surgery (TRUST).

> Results: We report 203 cases of unilateral and 68 cases of bilateral inquinal hernia repairs. Mean operative time was 74 ± 35 min (range 32-265 min), postoperative complications occurred in five (1.85%) cases, the intraoperative complication rate was five (1.85%). The average subjective patien

International Journal of Medical Robotics (Apr 2021)

Senhance surgical system in benian hysterectomy: A real-world comparative assessment of case times and instrument costs versus da Vinci robotics and laparoscopic-assisted vaginal hysterectomy procedures



- Senhance per procedure costs were less than half of da Vinci
- Senhance per procedure costs were in line with laparoscopy
- Case times between Senhance and da Vinci were comparable






Increasing Global Procedure Volumes


Senhance Demonstrating Strong Clinical Performance Across The Three Major Geographies

GLOBAL CLINICAL PROCEDURE VOLUME TREND



Accelerating procedure volumes

2022 PROCEDURE MIX



Utilization across multiple specialty areas, demonstrating broad applicability and adoption






Advancing Digital Capabilities Through Data Collection & Analysis

Increasing Surgical Data Improves Clinical Insight and Drives Consistently Superior Outcomes

Performance-Guided Surgery

Augmented Intelligence & Deep Learning Engine








Developing Next Generation Technology

Broadening Applicability of Senhance and Developing the Next Wave of PGS Technology





Business Update



KARL STORZ Agreement



- **10,000** OR1 installations globally
- 20% market share in the US and EU in integration
- 28% market share globally in imaging systems



- KARL STORZ will market and sell the ISU as a standalone device together with their IMAGE1 S™ imaging system and OR1™ integration solution
- The companies will work together on the integration of the ISU into KARL STORZ's laparoscopic vision systems
- The companies intend to jointly collaborate on developing nextgeneration instrumentation to be used with Asensus and surgical platforms



2022 Performance

- Over 3,100 procedures were performed globally: +29% over prior year
- Revenue: \$7.1MM
- Nine Senhance Surgical placements initiated
- Submitted FDA 510(k) application for pediatric indication in the U.S.
- December 31, 2022 Balance Sheet Highlights
 - Cash, cash equivalents, short-term and long-term investments ~\$74.4MM
 - No Debt



We Are Pioneering the Future of Surgery

10,000+

Procedures

100+

Surgeons

2,300+

Patient Registry

300+

Patents¹

Global

Regulatory Approvals 90+

Publications



Asensus Surgical

NYSE American: ASXC

Information for Investors

Visit our IR Website:

ir.asensus.com/

IR Contact:

invest@asensus.com

Sign Up for IR Email Alerts:

ir.asensus.com/email-alerts

Follow Us On Social Media



www.linkedin.com/company/asensus-surgical-inc



twitter.com/AsensusSurgical



voutube.com/c/transenterix



vimeo.com/asxc



www.tiktok.com/@asensus_surgical

Clinical Resources

Visit our Corporate Website:

asensus.com/

Explore Senhance:

senhance.com/us/home

Find Clinical Data:

senhance.com/us/resources

